AI filing briefs · archive
Every 8-K brief, with filters
The whole archive: 29,840 AI briefs of material SEC Form 8-K filings by 3,616 companies: 2,121 written within three weeks of the filing (filed since Oct 19, 2026) and 27,719 written later, for past filings. Pick a month, or filter by date, 8-K item, tone, impact, topic or ticker.
Briefs on record29,840every one kept
Companies3,616with at least one brief
Recent filings2,121filed since Oct 19, 2026
Past filings27,719written later, in Nov 2026
Nkarta reported initial clinical data for NKX019, its allogeneic CAR NK cell therapy candidate, in myositis and systemic sclerosis, based on small patient groups with limited follow-up. Among 40 patients treated across five indications, the company reported no deaths and no treatment discontinuations due to adverse events, and it has amended its dosing schedule and plans upcoming FDA discussions on registrational pathways.
- Myositis: 5 of 6 patients (83%) at the 4 billion-cell dose with at least three months of follow-up achieved moderate or major Total Improvement Score responses.
- Systemic sclerosis: 6 of 7 patients (86%) at the 4 billion-cell dose reached an rCRISS-25 response or greater by Day 90; 5 of 7 (71%) reached rCRISS-50.
- Safety: infusion-related reactions occurred in five patients (12.5%), mostly grade 1, and all resolved within 24 to 48 hours.
- Nkarta amended protocols to dose on Days 0, 2 and 4, plans to evaluate 6 billion cells per dose, and expects to report additional follow-up in the first half of 2027.
Read the filing on SEC.gov ↗
Marygold Companies reported results for the fiscal first quarter ended September 30, 2026. Revenue rose to $9.4 million from $5.2 million a year earlier, and net income was $1.8 million, or $0.04 per share, compared with a net loss of $0.4 million, or $0.01 per share. The company also disclosed a pending definitive merger agreement under which funds managed by Madison Dearborn Partners would acquire all outstanding shares for $2.00 per share.
- Revenue of $9.4 million for the quarter, up from $5.2 million a year earlier, excluding $1.5 million from discontinued New Zealand operations
- Net income of $1.8 million, or $0.04 per share, versus a net loss of $0.4 million, or $0.01 per share, a year earlier
- USCF Investments average assets under management rose to $5.5 billion from $2.9 billion a year earlier
- Pending merger at $2.00 per share by Madison Dearborn Partners, expected to close in the first half of 2027 or earlier
Read the filing on SEC.gov ↗
Veradermics reported positive topline 12-month results from Part B of Study '302', a Phase 2/3 trial of its lead candidate VDPHL01 in 519 men with mild-to-moderate pattern hair loss, and reported no new safety signals. The filing covers clinical trial data only and includes no revenue, earnings, or guidance figures, and the drug has not been approved for sale.
- Non-vellus hair count rose 43.9 hairs/cm2 (twice daily) and 29.7 hairs/cm2 (once daily) from baseline to Month 12 in the continued group.
- At Month 12, 89.1% (twice daily) and 79.8% (once daily) of continued-group participants reported visible improvement in hair coverage on the AAIRS scale.
- No treatment-related serious adverse events and no adverse event-related study discontinuations were reported between Month 6 and Month 12.
- The company plans to announce data from Study '306' in women in the first half of 2027.
Read the filing on SEC.gov ↗
KALA BIO reported preliminary, unaudited results for the quarter ended September 30, 2026, showing a net loss of approximately $0.8 million, down from $7.6 million a year earlier. Cash, cash equivalents and short-term investments were approximately $7.0 million with no debt, and the company expects to file its Form 10-Q on or about November 16, 2026. Final results may differ from these preliminary figures, which shareholders should weigh against the pending review.
- Q3 2026 net loss of approximately $0.8 million vs. $7.6 million in Q3 2025
- Nine-month 2026 net loss of approximately $4.0 million vs. $27.7 million in the same period of 2025
- Cash, cash equivalents and short-term investments of approximately $7.0 million as of September 30, 2026, with no debt
- Form 10-Q expected on or about November 16, 2026; results remain preliminary and unaudited
Read the filing on SEC.gov ↗
Telos Corporation reported third quarter 2026 revenue of $55.2 million, up from $51.4 million a year earlier, and GAAP net income of $4.4 million, or $0.06 per diluted share, compared with a net loss of $2.1 million a year earlier. The company also raised its full-year 2026 revenue and adjusted EBITDA outlook, which points to stronger results for shareholders.
- Q3 2026 revenue was $55.2 million, versus $51.4 million in Q3 2025.
- GAAP net income was $4.4 million ($0.06 per diluted share), compared with a net loss of $2.1 million ($0.03 per share) a year earlier.
- Full-year 2026 revenue outlook was raised to $198.2 million-$200.7 million from $187 million-$195 million.
- Full-year 2026 adjusted EBITDA outlook was raised to $32.3 million-$34.1 million from $23.6 million-$28.6 million.
Read the filing on SEC.gov ↗
United-Guardian reported higher third-quarter 2026 results, with net sales up 54% to $3,494,780 and net income up 247% to $930,912, or $0.20 per share. For the first nine months, net sales rose 25% to $9,475,269 and net income rose 70% to $2,478,393, or $0.54 per share, showing growth in both periods for shareholders.
- Q3 2026 net sales were $3,494,780, up 54% from $2,264,261 in Q3 2025.
- Q3 2026 net income was $930,912 ($0.20 per share), up 247% from $268,441 ($0.06 per share).
- Nine-month 2026 net sales were $9,475,269, up 25%; net income was $2,478,393 ($0.54 per share), up 70%.
- Pharmaceutical sales grew 29% in the quarter, driven primarily by Renacidin; cosmetic ingredient sales rose 187%.
Read the filing on SEC.gov ↗
Vir Biotechnology said its pivotal Phase 3 ECLIPSE 1 trial of elebsiran and tobevibart in adults with chronic hepatitis delta met its primary and key secondary endpoints, with data presented at the AASLD Liver Meeting on November 8, 2026. The company also released expanded Phase 2 SOLSTICE data and preliminary, exploratory findings on treatment discontinuation, which the company itself says are interim and not a complete assessment of safety or efficacy.
- ECLIPSE 1 primary endpoint: 44% of patients on elebsiran and tobevibart reached undetectable virus plus ALT normalization at Week 48, versus 0% in the delayed treatment group at Week 12 (p<0.0001)
- Key secondary endpoint: 79% reached undetectable virus at Week 48, versus 0% in the delayed treatment group
- SOLSTICE Week 96: 100% (28/28) of patients who completed Week 96 of combination therapy reached undetectable viremia
- Exploratory analysis: 10 patients discontinued treatment; all 10 achieved SVR12, with 7 reaching SVR24 and 1 reaching SVR48; the filing states these data are preliminary and not a claim of cure
Read the filing on SEC.gov ↗
Mereo BioPharma reported a third-quarter 2026 net loss of $5.9 million, down from $7.0 million a year earlier, as research and development and general and administrative expenses fell and the company recorded $800 thousand of revenue versus none a year earlier. Cash and cash equivalents were $26.1 million at September 30, 2026, which the company says should fund operations into late 2027, excluding any potential option payments from Sentynl Therapeutics.
- Q3 2026 net loss was $5.9 million, compared with $7.0 million in Q3 2025; nine-month net loss was $19.6 million versus $34.5 million a year earlier.
- Q3 2026 revenue was $800 thousand, compared with no revenue in Q3 2025; R&D expenses fell to $2.1 million from $4.3 million and G&A expenses fell to $4.9 million from $6.0 million.
- Cash and cash equivalents were $26.1 million at September 30, 2026, down from $41.0 million at December 31, 2025.
- Sentynl's exercise of its alvelestat option would bring $40 million in upfront and R&D payments; Mereo expects to provide an FDA-related update before the end of 2026.
Read the filing on SEC.gov ↗
ADC Therapeutics reported third quarter 2026 results, with net product revenue of $21.0 million, up from $15.8 million a year earlier, and a net loss of $25.3 million, or $0.16 per share, versus $41.0 million, or $0.30 per share, in the prior-year quarter. Cash and cash equivalents were $189.2 million at September 30, 2026, down from $261.3 million at December 31, 2025, and the company said its October 2026 financing restructuring extends its expected cash runway into 2029.
- Q3 2026 net product revenue was $21.0 million, compared with $15.8 million in Q3 2025; license revenue and royalties were $0.7 million in both periods.
- Q3 2026 net loss was $25.3 million ($0.16 per share), compared with $41.0 million ($0.30 per share) a year earlier; adjusted net loss was $8.8 million.
- Cash and cash equivalents were $189.2 million at September 30, 2026, versus $261.3 million at December 31, 2025.
- October 2026 restructuring included an $86.6 million PIPE financing, elimination of a $150 million change-of-control payment, and a reduction of the senior secured loan principal by $68.5 million to $50 million.
Read the filing on SEC.gov ↗
Delcath Systems reported third-quarter 2026 revenue of $35.1 million, up from $20.6 million a year earlier, and net income of $7.0 million, compared with $0.8 million. The company raised its full-year 2026 revenue guidance to $115 million to $117 million, which signals continued growth in HEPZATO KIT sales for shareholders.
- Q3 2026 net income of $7.0 million, or $0.17 diluted per share, versus $0.8 million, or $0.02 per share, in Q3 2025
- Q3 2026 HEPZATO KIT revenue of $32.7 million, up from $19.3 million; non-GAAP adjusted EBITDA of $11.5 million, up from $5.3 million
- 2026 guidance raised to $115 million to $117 million in total revenue, with gross margins of 87% to 89% and positive adjusted EBITDA
- Cash and investments of $104.3 million as of September 30, 2026, with no debt
Read the filing on SEC.gov ↗
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.